文献速递中毒与环境急症心脑血管急症重症综合管理与镇静镇痛

甲醇中毒性视神经病变后慢性视觉通路变化的临床与遗传决定因素:四年随访研究

Clinical and genetic determinants of chronic visual pathway changes after methanol - induced optic neuropathy: four-year follow-up study.
PubMed 文献 · Clin Toxicol (Phila) · 2018-11-17
一句话结论甲醇中毒后4年内超过80%患者视神经传导改善,但诱发电位波幅倾向下降,ApoE4携带者视觉功能异常风险显著更高。

该研究对42例确诊甲醇中毒患者出院后4.9、25.0和49.9个月进行随访,行视觉诱发电位、视网膜神经纤维层测量、脑MRI、眼科检查及ApoE基因分型。结果显示右眼18/42、左眼21/42存在P1潜伏期异常,随访期间36/42(86%)右眼和35/42(83%)左眼P1潜伏期平均缩短15.0±2.0 ms和14.9±2.4 ms,但N1P1波幅无显著变化,47%可测波幅患者至少一眼波幅进一步下降≥1.0 mcV。ApoE4携带者整体及颞侧RNFL更薄、初始P1潜伏期更长,视觉功能异常OR为8.92(95%CI 3.00-36.50),且与脑坏死病灶和脑出血相关。结论提示甲醇中毒后视神经传导多数改善,但波幅倾向下降,ApoE4携带者视觉及脑损害更重。

要点

  • 甲醇中毒后4年内,86%右眼和83%左眼P1潜伏期平均缩短15.0±2.0 ms和14.9±2.4 ms,最大缩短达35.0 ms。
  • 随访期间N1P1波幅无显著变化,但47%(17/36)可测波幅患者至少一眼波幅进一步下降≥1.0 mcV。
  • ApoE4携带者视觉功能异常OR为8.92(95%CI 3.00-36.50,p<.001),整体及颞侧RNFL更薄、初始P1潜伏期更长(均p<.05)。
  • ApoE4携带者脑坏死病灶(r=0.384,p=.013)和脑出血(r=0.395,p=.011)更常见。

适用人群与场景

  • 确诊甲醇中毒的患者,平均年龄45.7±4.4岁,出院后4.9±0.6、25.0±0.6和49.9±0.5个月随访。

研究设计与关键结果

  • 研究类型为四年随访研究,共42例确诊甲醇中毒患者,随访时间点分别为出院后4.9±0.6、25.0±0.6和49.9±0.5个月。
  • 视觉诱发电位P1潜伏期异常:右眼18/42,左眼21/42;N1P1波幅异常:右眼和左眼各10/42。
  • 随访期间P1潜伏期平均缩短:右眼15.0±2.0 ms(36/42,86%),左眼14.9±2.4 ms(35/42,83%),最大缩短35.0 ms。
  • N1P1平均波幅随访期间无显著变化。
  • 至少一眼N1P1波幅进一步下降≥1.0 mcV者17/36(47%),平均下降右眼-1.11±0.83 mcV、左眼-2.37±0.66 mcV, vs 研究人群右眼-0.06±0.56 mcV、左眼-0.83±0.64 mcV,均p<.001。
  • ApoE4携带者整体及颞侧RNFL厚度更低、初始P1潜伏期更长(均p<.05);视觉功能异常OR 8.92(95%CI 3.00-36.50,p<.001)。
  • ApoE4携带者与脑坏死病灶(r=0.384,p=.013)和脑出血(r=0.395,p=.011)相关。

证据类型、等级与局限

  • 证据类型:四年随访研究(队列研究)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为甲醇中毒后视神经传导在多数患者中改善,但诱发电位波幅倾向下降,ApoE4携带者视觉功能异常及脑损害风险更高。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

CONTEXT: Methanol poisoning induces acute optic neuropathy with possible long-term visual damage.

OBJECTIVE: To study the dynamics and key determinants of visual pathway functional changes during 4 years after acute methanol poisoning.

METHODS: A total of 42 patients with confirmed methanol poisoning (mean age 45.7 ± 4.4 years) were examined 4.9 ± 0.6, 25.0 ± 0.6, and 49.9 ± 0.5 months after discharge. The following tests were performed: visual evoked potential (VEP), retinal nerve fiber layer (RNFL) measurement, brain magnetic resonance imaging (MRI), complete ocular examination, biochemical tests, and apolipoprotein E (ApoE) genotyping.

RESULTS: Abnormal VEP P1 latency was registered in 18/42 right eyes (OD) and 21/42 left eyes (OS), abnormal N1P1 amplitude in 10/42 OD and OS. Mean P1 latency shortening during the follow-up was 15.0 ± 2.0 ms for 36/42 (86%) OD and 14.9 ± 2.4 ms for 35/42 (83%) OS, with maximum shortening up to 35.0 ms. No significant change of mean N1P1 amplitude was registered during follow-up. A further decrease in N1P1 amplitude ≥1.0 mcV in at least one eye was observed in 17 of 36 patients (47%) with measurable amplitude (mean decrease -1.11 ± 0.83 (OD)/-2.37 ± 0.66 (OS) mcV versus -0.06 ± 0.56 (OD)/-0.83 ± 0.64 (OS) mcV in the study population; both p < .001). ApoE4 allele carriers had lower global and temporal RNFL thickness and longer initial P1 latency compared to the non-carriers (all p < .05). The odds ratio for abnormal visual function was 8.92 (3.00-36.50; 95%CI) for ApoE4 allele carriers (p < .001). The presence of ApoE4 allele was further associated with brain necrotic lesions (r = 0.384; p = .013) and brain hemorrhages (r = 0.395; p = .011).

CONCLUSIONS: Improvement of optic nerve conductivity occurred in more than 80% of patients, but evoked potential amplitude tended to decrease during the 4 years of observation. ApoE4 allele carriers demonstrated lower RNFL thickness, longer P1 latency, and more frequent methanol-induced brain damage compared to non-carriers.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Nurieva O, Hubacek JA, Urban P, et al. Clinical and genetic determinants of chronic visual pathway changes after methanol - induced optic neuropathy: four-year follow-up study. Clin Toxicol (Phila). 2018. PMID: 30451020. doi:10.1080/15563650.2018.1532083

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。